Last Updated : October 31, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Lynparza | olaparib | gBRCAm, HER2-negative high-risk early breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Lynparza | olaparib | Breast Cancer | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | ||
Lynparza | Olaparib | Newly Diagnosed OC | Reimburse with clinical criteria and/or conditions | Complete | ||
Lynparza | Olaparib | metastatic castration-resistant prostate cancer (mCRPC) | Reimburse with clinical criteria and/or conditions | Complete | ||
Lynparza | olaparib | Metastatic castration-resistant prostate cancer (mCRPC) | Reimburse with clinical criteria and/or conditions | Complete | ||
Lynparza | Olaparib | Ovarian Cancer | Do not reimburse | Complete | ||
Lynparza (Resubmission) | Olaparib | Ovarian Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Lyrica | Pregabalin | Pain, Neuropathic | Do not list | Complete | ||
Lyrica | Pregabalin | diabetic peripheral neuropathy | Do not list | Complete | ||
Macugen | Pegaptanib sodium | Macular degeneration, age-related | Do not list | Complete |